0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Insights, Forecast to 2028
Published Date: April 2022
|
Report Code: QYRE-Auto-0N4529
Home | Market Reports | Health | Health Conditions | Neurological Conditions
Global Transthyretin amyloid cardiomyopathy ATTR CM Treatment Market Insights Forecast to 2028

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Insights, Forecast to 2028

Code: QYRE-Auto-0N4529
Report
April 2022
95 Pages
QYResearch
Region: Global, North America, Europe, Canada, UAE, Saudi Arabia, Turkey, Southeast Asia, France, Germany, South Korea, Italy, Russia,
Description
Table of Content
Tables & Figures
Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.
Market Analysis and Insights: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market

The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

Fully considering the economic change by this health crisis, Transthyretin Stabilizers accounting for % of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Hereditary Transthyretin Amyloidosis (hATTR) segment is altered to an % CAGR throughout this forecast period.
China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size is valued at US$ million in 2021, while the North America and Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market.
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Scope and Market Size
Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Transthyretin Stabilizers
Nonsteroidal Anti-inflammatory Drugs (NSAID)
RNAi Therapy
Others

Segment by Application

Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)

BY COMPANY

Pfizer Inc
GlaxoSmithKline Plc
Eidos Therapeutics
Ionis Pharmaceuticals, Inc
Alnylam Pharmaceuticals
Prothena Corporation Plc
Intellia Therapeutics, Inc
Corino Therapeutics, Inc

BY REGION

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Transthyretin Stabilizers
1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
1.2.4 RNAi Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hereditary Transthyretin Amyloidosis (hATTR)
1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR)
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2017-2028)
2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Region
2.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Region (2017-2022)
2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Region (2023-2028)
2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Dynamics
2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Trends
2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue
3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2017-2022)
3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue
3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio
3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2021
3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served
3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type
4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2017-2022)
4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2023-2028)
5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application
5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2017-2022)
5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028)
6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
6.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022)
6.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028)
6.2.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028)
6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
6.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022)
6.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028)
6.3.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028)
6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
6.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022)
6.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028)
7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
7.2.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022)
7.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028)
7.2.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028)
7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
7.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022)
7.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028)
7.3.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028)
7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
7.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022)
7.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028)
8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
8.2.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
8.3.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.4.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028)
9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
9.2.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028)
9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
9.3.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028)
9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
9.4.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028)
10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
10.2.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
10.3.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
10.4.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Company Details
11.1.2 Pfizer Inc Business Overview
11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
11.1.5 Pfizer Inc Recent Developments
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Details
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
11.2.5 GlaxoSmithKline Plc Recent Developments
11.3 Eidos Therapeutics
11.3.1 Eidos Therapeutics Company Details
11.3.2 Eidos Therapeutics Business Overview
11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
11.3.5 Eidos Therapeutics Recent Developments
11.4 Ionis Pharmaceuticals, Inc
11.4.1 Ionis Pharmaceuticals, Inc Company Details
11.4.2 Ionis Pharmaceuticals, Inc Business Overview
11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
11.4.5 Ionis Pharmaceuticals, Inc Recent Developments
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
11.5.5 Alnylam Pharmaceuticals Recent Developments
11.6 Prothena Corporation Plc
11.6.1 Prothena Corporation Plc Company Details
11.6.2 Prothena Corporation Plc Business Overview
11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
11.6.5 Prothena Corporation Plc Recent Developments
11.7 Intellia Therapeutics, Inc
11.7.1 Intellia Therapeutics, Inc Company Details
11.7.2 Intellia Therapeutics, Inc Business Overview
11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
11.7.5 Intellia Therapeutics, Inc Recent Developments
11.8 Corino Therapeutics, Inc
11.8.1 Corino Therapeutics, Inc Company Details
11.8.2 Corino Therapeutics, Inc Business Overview
11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
11.8.5 Corino Therapeutics, Inc Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
    Table 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Transthyretin Stabilizers
    Table 3. Key Players of Nonsteroidal Anti-inflammatory Drugs (NSAID)
    Table 4. Key Players of RNAi Therapy
    Table 5. Key Players of Others
    Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2017-2022)
    Table 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2023-2028)
    Table 12. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
    Table 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
    Table 14. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
    Table 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
    Table 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Players (2017-2022)
    Table 18. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2021)
    Table 19. Ranking of Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
    Table 23. Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2017-2022)
    Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2023-2028)
    Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Application (2017-2022)
    Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Application (2023-2028)
    Table 33. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 34. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 35. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 36. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 37. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 38. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 40. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 41. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 42. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 43. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 44. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 45. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 46. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 49. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 50. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2023-2028) & (US$ Million)
    Table 51. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 52. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 53. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 54. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 55. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 56. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 57. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 61. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 62. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 63. Pfizer Inc Company Details
    Table 64. Pfizer Inc Business Overview
    Table 65. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 66. Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million)
    Table 67. Pfizer Inc Recent Developments
    Table 68. GlaxoSmithKline Plc Company Details
    Table 69. GlaxoSmithKline Plc Business Overview
    Table 70. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 71. GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million)
    Table 72. GlaxoSmithKline Plc Recent Developments
    Table 73. Eidos Therapeutics Company Details
    Table 74. Eidos Therapeutics Business Overview
    Table 75. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 76. Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million)
    Table 77. Eidos Therapeutics Recent Developments
    Table 78. Ionis Pharmaceuticals, Inc Company Details
    Table 79. Ionis Pharmaceuticals, Inc Business Overview
    Table 80. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 81. Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million)
    Table 82. Ionis Pharmaceuticals, Inc Recent Developments
    Table 83. Alnylam Pharmaceuticals Company Details
    Table 84. Alnylam Pharmaceuticals Business Overview
    Table 85. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 86. Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million)
    Table 87. Alnylam Pharmaceuticals Recent Developments
    Table 88. Prothena Corporation Plc Company Details
    Table 89. Prothena Corporation Plc Business Overview
    Table 90. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 91. Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million)
    Table 92. Prothena Corporation Plc Recent Developments
    Table 93. Intellia Therapeutics, Inc Company Details
    Table 94. Intellia Therapeutics, Inc Business Overview
    Table 95. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 96. Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million)
    Table 97. Intellia Therapeutics, Inc Recent Developments
    Table 98. Corino Therapeutics, Inc Company Details
    Table 99. Corino Therapeutics, Inc Business Overview
    Table 100. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
    Table 101. Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million)
    Table 102. Corino Therapeutics, Inc Recent Developments
    Table 103. Research Programs/Design for This Report
    Table 104. Key Data Information from Secondary Sources
    Table 105. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type: 2021 VS 2028
    Figure 2. Transthyretin Stabilizers Features
    Figure 3. Nonsteroidal Anti-inflammatory Drugs (NSAID) Features
    Figure 4. RNAi Therapy Features
    Figure 5. Others Features
    Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2021 VS 2028
    Figure 7. Hereditary Transthyretin Amyloidosis (hATTR) Case Studies
    Figure 8. Wild Type Transthyretin Amyloidosis (wtATTR) Case Studies
    Figure 9. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Report Years Considered
    Figure 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region: 2021 VS 2028
    Figure 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players in 2021
    Figure 14. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2021
    Figure 16. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 17. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 18. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 19. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Country (2017-2028)
    Figure 20. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 23. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 24. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 25. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Country (2017-2028)
    Figure 26. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Nordic Countries Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 33. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 34. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 35. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Region (2017-2028)
    Figure 36. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Australia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 42. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 43. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 44. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 45. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Country (2017-2028)
    Figure 46. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 49. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 50. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 51. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Country (2017-2028)
    Figure 52. Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Pfizer Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
    Figure 56. GlaxoSmithKline Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
    Figure 57. Eidos Therapeutics Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
    Figure 58. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
    Figure 59. Alnylam Pharmaceuticals Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
    Figure 60. Prothena Corporation Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
    Figure 61. Intellia Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
    Figure 62. Corino Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$4900
This license allows only one user(purchaser of the report) to access the PDF.

Electronic (PDF)
$7350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$9800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano Dimension
SIMILAR REPORTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global and United States Autism Spectrum Disorder Diagnostics Market Report Forecast 2022 2028
Global and United States Autism Spectrum Disorder Diagnostics Market Report & Forecast 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-32L5829
Tue Jun 07 00:00:00 UTC 2022

Add to Cart

Global Monosialotetrahexosylganglioside Market Insights and Forecast to 2028
Global Monosialotetrahexosylganglioside Market Insights and Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-35G1831
Tue May 03 00:00:00 UTC 2022

Add to Cart

Global Neurodegenerative Diseases Drug Market Insights and Forecast to 2028
Global Neurodegenerative Diseases Drug Market Insights and Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-33M1920
Tue May 03 00:00:00 UTC 2022

Add to Cart

Global Unilateral Vocal Cord Paralysis Treatment Market Insights Forecast to 2028
Global Unilateral Vocal Cord Paralysis Treatment Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-11B5968
Thu Apr 21 00:00:00 UTC 2022

Add to Cart